Molecular lung cancer test identifies patients at high risk of death even after surgery

November 2, 2012 by Jason Bardi

(Medical Xpress)—One of the toughest issues facing patients who have surgery for very early-stage lung cancer is uncertainty: Despite complete removal of their small lung tumors and no evidence of metastasis, at least one quarter of patients harbor tiny, undetectable clumps of cancer cells that have already spread outside their lungs and will kill them within a few years.

Doctors have no way of telling which cancers will recur, and, as a result, none of these receives chemotherapy that might otherwise reduce their chance of dying from the disease.

A new molecular test developed by doctors at the University of California, San Francisco (UCSF) may give doctors the ability to better predict post-operative early-stage mortality. This week in the  (JAMA), the team reports that the test effectively identifies patients with a high likelihood of recurrence even of this very early form of cancer, which is called "T1a node-negative non-squamous, non-small cell lung cancer."

The involved analyzing tumors from 1,439 patients in the United States and China who underwent surgery during the last 15 years. These patients belonged to either the Kaiser Permanente Northern California System or had gone to one of three hospitals in that participate in the China Clinical Trials Consortium.

The study showed that the scientists could accurately stratify patients even with the earliest stage of lung cancer into groups at low-, intermediate- or high-risk of death based solely on the activity of 14 different genes found in their tumors. The prognostic information obtained from this molecular analysis of an individual tumor's biology significantly surpassed the information that could be obtained from any conventional prognostic criteria derived either from of the tumors, or from the patients' clinical situations.

"This group of patients with very early disease is expected to increase as screening for lung cancer is more widely implemented," said UCSF thoracic surgeon Michael Mann, MD. A number of hospitals around the country, including UCSF Medical Center, have implemented lung cancer screening programs in the last two years.

More Hope for Lung Cancer Survival

Published guidelines currently recommend chemotherapy for stage I lung cancer patients who are thought to be at very high risk of recurrence. These guidelines, however, provide no criteria to aid in the identification of high-risk patients with T1a node-negative disease.

The UCSF team and their colleagues previously demonstrated that the new assay better identifies high-risk stage I patients than the published criteria. It remained uncertain, however, if high-risk patients could also be identified from among the growing number of patients with the earliest, T1a node-negative cancers. The new report now confirms that the test can successfully identify patients even in this group who have a 50 percent chance of death, and for whom further intervention might also need to be considered.

Lung cancer is currently the most lethal cancer in the world, largely because of its propensity to spread even at very early stages of the disease. As a result, lung cancer is most often diagnosed after it has become incurable. Doctors hope that screening for lung cancer will lead to earlier detection and increase overall survival from the disease, which has not improved after 40 years of research. Identification of patients with these early tumors who are still at high risk of death may further improve the benefit derived from early detection.

Mann is one of several doctors at UCSF who jointly developed the technology upon which the test is based. The test itself was developed by Pinpoint Genomics, a company that was acquired in 2012 by Life Technologies Corp., which is currently making the test available to clinicians throughout the United States. Importantly, the test can be run on standard pathology specimens and does not require any special handling of the tumor tissues.

The article, "Ability of a Prognostic Assay to Identify Patients at High Risk of Mortality Despite Small, Node-Negative " by Johannes R. Kratz, Stephen K. Van Den Eeden, Jianxing He, David M. Jablons and Michael J. Mann, was published by JAMA on Oct. 23, 2012.

Lung Cancer Statistics

  • 226,160 new cases of lung cancer will be diagnosed in 2012
  • 160,340 lung cancer deaths expected in 2012
  • 6.94% of people born today will be diagnosed with lung cancer during their lifetime
  • 1.4 million deaths worldwide caused by lung cancer every year
  • $10.3 billion spent in the United States each year on lung cancer treatment
  • $281.9 million invested by NCI in lung cancer research in 2010

Explore further: New lung cancer test predicts survival

Related Stories

New lung cancer test predicts survival

January 26, 2012
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco (UCSF) has demonstrated that an available ...

Crizotinib reduces tumor size in patients with ALK positive lung cancer

September 6, 2012
Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard ...

Many lung cancer patients get radiation therapy that may not prolong their lives

February 13, 2012
A new study has found that many older lung cancer patients get treatments that may not help them live longer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest ...

Trial seeks to sniff out lung cancer

June 19, 2012
Cancer smells different. Past research has shown that dogs can detect lung cancer in a person’s breath with great accuracy. But dogs are  tricky to use as a diagnostic tool; what does it mean when a dog barks once ...

Recommended for you

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.